Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
60 participants
INTERVENTIONAL
2025-03-18
2027-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
AtriCure Bipolar Radiofrequency Ablation of Permanent Atrial Fibrillation
NCT00560885
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
NCT06165510
AtriCure Bipolar Radiofrequency Ablation of Persistent Atrial Fibrillation
NCT00785902
CONVERGE - Epi/Endo Ablation For Treatment of Persistent Atrial Fibrillation(AF)
NCT01984346
Dual Epicardial Endocardial Persistent Atrial Fibrillation (AF) Study
NCT01246466
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Pulmonary vein isolation using PFA energy
2. Pulmonary vein isolation and posterior wall isolation using PFA energy
3. Pulmonary vein isolation and posterior wall isolation (PFA) and mitral isthmus ablation using RFA or PFA energy.
Patients will receive an implantable loop recorder prior to, during or post index ablation procedure for continuous monitoring for clinical recurrence of AF/AT/AFL
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PVI using PFA energy
Pulmonary vein isolation using PFA energy
Catheter Ablation
This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:
PVI and posterior wall isolation using PFA energy
Pulmonary vein isolation and posterior wall isolation using PFA energy
Catheter Ablation
This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:
PVI and posterior wall isolation (PFA) and mitral isthmus ablation using RFA or PFA energy.
Pulmonary vein isolation and posterior wall isolation (PFA) and mitral isthmus ablation using RFA or PFA energy.
Catheter Ablation
This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Catheter Ablation
This is a prospective randomized clinical trial. Patients will undergo catheter ablation for persistent AF using a lattice-tip catheter that can switch between RFA and PFA energy. Enrolled patients will be randomized to one of three ablation strategies:
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
(1a) a physician's note indicating symptoms consistent with AF sustained longer than 7 days but less than 12 months; AND electrocardiographic evidence
2\. . Suitable candidate for catheter ablation.
3\. . Adults aged 18 - 80 years.
4\. . Willing and able to comply with all baseline and follow-up evaluations for the full length of the study.
Exclusion Criteria
2. Previous left atrial ablation or surgical procedure (including septal closure or left atrial appendage closure).
3. Valvular cardiac surgical/percutaneous procedure (e.g., ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve).
4. Any carotid stenting or endarterectomy.
5. Any cardiac procedure (surgical or percutaneous) or percutaneous coronary intervention within the 90 days prior to the initial procedure.
6. Coronary artery bypass graft (CABG) procedure within the 6 months prior to the initial procedure.
7. Awaiting cardiac transplantation or other cardiac surgery within the 12 months following the initial ablation procedure.
8. Documented thromboembolic event (stroke or transient ischemic attack) within 6 months (180 days) prior to the initial ablation procedure.
9. Documented left atrial thrombus on imaging.
10. History of blood clotting or bleeding abnormalities.
11. Any condition contraindicating chronic anticoagulation.
12. Myocardial infarction (MI) within the 3 months (90 days) prior to the initial procedure.
13. Body mass index \>40 kg/m2.
14. Left atrial diameter \>55 mm (anterioposterior).
15. Diagnosed atrial myxoma.
16. Uncontrolled heart failure or NYHA Class III or IV heart failure.
17. Rheumatic heart disease.
18. Hypertrophic cardiomyopathy.
19. Unstable angina.
20. Moderate to severe mitral valve stenosis.
21. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2).
22. Primary pulmonary hypertension.
23. Significant restrictive or obstructive pulmonary disease or chronic respiratory condition.
24. Renal failure requiring dialysis.
25. History of severe Gastroesophageal Reflux Disease (GERD) requiring surgical and/or mechanical intervention.
26. Acute illness, active systemic infection, or sepsis.
27. Contraindication to both computed tomography and magnetic resonance angiography.
28. Significant congenital anomaly or medical problem that, in the opinion of the investigator, would preclude enrollment in this study or compliance with follow-up requirements or would impact the scientific soundness of the clinical study results.
29. Current or anticipated participation in any other clinical study of a drug, device, or biologic during the duration of the study not pre-approved by the Sponsor.
30. Presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation.
31. Known drug or alcohol dependency.
32. Life expectancy less than 12 months.
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Stavros E Mountantonakis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stavros E Mountantonakis
Director, Cardiac Electrophysiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stavros Mountantonakis, MD
Role: PRINCIPAL_INVESTIGATOR
Northwell Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
North Shore University Hospital
Manhasset, New York, United States
Long Island Jewish Medical Center
New Hyde Park, New York, United States
Kristie Coleman
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-0935-LHH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.